NEW YORK (GenomeWeb) – Molecular diagnostics and life sciences research tools firm Luminex announced today that it will acquire molecular diagnostics company Nanosphere in an all-cash transaction valued at approximately $58 million.
The transaction values Nanosphere at $1.35 per share, Luminex said. The company will also pay or help Nanosphere pay $25 million in debt outstanding as of March 31. Net of acquired cash, the total deal is valued at $72 million. Both companies' boards have unanimously approved the deal, which is expected to close on or before July 1.